Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl- secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands[1].
Stepronin (0.1-100 µM; 20 min) induces significant reductions in ISOP(Isoproterenol)-evoked SCC (short circuit current) value in a dose-dependent manner in canine tracheal epithelium[1].
Stepronin (10-100 µM; 20 min) significantly inhibits the basal secretion and ISOP-evoked PD (potential difference) value in a dose-dependent manner in canine tracheal epithelium[1].
Stepronin (100 µM; 20 min) significantly inhibits ISOP-induced [3H]-glycoconjugate secretion in submucosal glands[1].
Cell Viability Assay[1]
| Cell Line: | Canine tracheal epithelium (from adult and 10 to 25 kg-weight mongrel dogs of both sexes) |
| Concentration: | 0.1-100 µM; 10-100 µM |
| Incubation Time: | 20 min (pre-treat) |
| Result: | Significantly inhibited ISOP-induced SCC and PD values, as well as basal secretion. |
Cell Viability Assay[1]
| Cell Line: | Submucosal glands (from adult and 10 to 25 kg-weight mongrel dogs of both sexes) |
| Concentration: | 100 µM |
| Incubation Time: | 20 min (pre-treat) |
| Result: | Significantly inhibited ISOP- induced [3H]-glycoconjugate secretion. |
[1]. Yamada K, et al. An expectorant, stepronin, reduces airway secretion in vitro. Respiration. 1994;61(1):42-7.